An Open-Label Extension Study of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms PERFECTOLE
- Sponsors United Therapeutics Corporation
Most Recent Events
- 05 Jan 2023 Status changed from active, no longer recruiting to discontinued.
- 07 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 10 Dec 2020 Planned End Date changed from 31 Dec 2020 to 31 Jul 2025.